Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.81 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.81 |
| ▸ | TSHR | P16473 | 2/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.81 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | RGS12 | O14924 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.81 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.71 |
| ▸ | HTR1A | P08908 | 1/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8292280 | 0.91 | LMNA (0.78) | PKMHIF1ALMNACYP1A2CYP3A4 | |
| SCHEMBL8647358 | 0.90 | LMNA (0.77) | PKMHIF1ALMNACYP1A2CYP3A4 | |
| SCHEMBL1322507 | 0.90 | LMNA (1.00) | PKMHIF1ALMNACYP1A2CYP3A4 | |
| SCHEMBL8296317 | 0.85 | LMNA (0.69) | PKMHIF1ALMNACYP1A2CYP3A4 | |
| SCHEMBL6900389 | 0.85 | PTGS2 (0.75) | PKMHIF1ALMNACYP1A2CYP3A4 | |
| SCHEMBL14446495 | 0.84 | LMNA (0.89) | PKMHIF1ALMNACYP1A2CYP3A4 | |
| SCHEMBL7962081 | 0.83 | PLA2G2A (0.80) | PKMHIF1ALMNACYP1A2CYP3A4 | |
| Acemetacin SCHEMBL23843 | 0.83 | PTGS2 (1.00) | PKMHIF1ALMNACYP1A2CYP2C9 | |
| Acemetacin SCHEMBL29402955 | 0.83 | PTGS2 (1.00) | PKMHIF1ALMNACYP1A2CYP2C9 | |
| SCHEMBL8296825 | 0.82 | LMNA (0.66) | PKMHIF1ALMNACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1429807-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA Pharma AG (DE) | 2004-06-23 | — | — | EP | claimed |
| WO-2003024489-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | claimed |
| EP-1501837-A1 | CASCADE ESTERS OF CAMPTOTHECINS AND METHODS OF TREATING CANCER USING THESE COMPOUNDS | THE STEHLIN FOUNDATION FOR CANCER RESEARCH (US) | 2005-02-02 | — | — | EP | disclosed |
| US-6699875-B2 | Cascade esters of camptothecins and methods of treating cancer using these compounds | THE STEHLIN FOUNDATION FOR CANCER RESEARCH | 2004-03-02 | — | — | US | disclosed |
| US-20030216421-A1 | Cascade esters of camptothecins and methods of treating cancer using these compounds | GIOVANELLA, BEPPINO | 2003-11-20 | — | — | US | disclosed |
| WO-2003095460-A1 | CASCADE ESTERS OF CAMPTOTHECINS AND METHODS OF TREATING CANCER USING THESE COMPOUNDS | THE STEHLIN FOUNDATION FOR CANCER RESEARCH (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216421-A1 | Cascade esters of camptothecins and methods of treating cancer using these compounds | CREB1, ATF4, PRKAR2B | PKM 1901/4885HIF1A 1053/4885LMNA 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.